In conclusion, these findings provide new insights into the oncogenic role of YBX1 in glycolysis and suggest that the YBX1-LDHA-NF-κB axis may represent a promising therapeutic target of RCC. The gene discussed is NFKB1; the disease is renal cell carcinoma.